Patents by Inventor Rudolf-Giesbert Alken

Rudolf-Giesbert Alken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180338943
    Abstract: Herein described are deuterated catecholamine derivatives of the general Formula I wherein, R1 is deuterium, R2, and R3 are independently selected from hydrogen and deuterium and wherein at least one of R2 and R3 has a deuterium enrichment in the range from 0.02 mol % to 100 mol % deuterium, and wherein the deuterium enrichment of R2 and R3 is different from each other and that the difference between the deuterium enrichment of R2 and R3 is at least 5 percentage points, R4 is hydrogen, deuterium, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or C5 to C6-cycloalkyl, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions, as well as their physiologically acceptable salts and their stereoisomers, enantiomers or diastereomers in optically pure form. The compounds can easily be prepared by mixing deuterated and non-deuterated compounds in a predefined ratio. The compounds show anti-Parkinson effect at lower doses and show lower side effects.
    Type: Application
    Filed: May 31, 2018
    Publication date: November 29, 2018
    Inventors: Rudolf-Giesbert ALKEN, Frank SCHNEIDER
  • Publication number: 20180280511
    Abstract: The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Inventors: David S. Goldstein, Courtney Holmes, Rudolf-Giesbert Alken, Frank Schneider, Chengzhi Zhang
  • Publication number: 20180116989
    Abstract: Herein described are deuterated catecholamine derivatives of the general Formula I wherein, R1 is deuterium, R2, and R3 are independently selected from hydrogen and deuterium and wherein at least one of R2 and R3 has a deuterium enrichment in the range from 0.02 mol % to 100 mol % deuterium, and wherein the deuterium enrichment of R2 and R3 is different from each other and that the difference between the deuterium enrichment of R2 and R3 is at least 5 percentage points, R4 is hydrogen, deuterium, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or C5 to C6-cycloalkyl, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions, as well as their physiologically acceptable salts and their stereoisomers, enantiomers or diastereomers in optically pure form. The compounds can easily be prepared by mixing deuterated and non-deuterated compounds in a predefined ratio. The compounds show anti-Parkinson effect at lower doses and show lower side effects.
    Type: Application
    Filed: August 16, 2017
    Publication date: May 3, 2018
    Inventors: Rudolf-Giesbert ALKEN, Frank SCHNEIDER
  • Publication number: 20170319694
    Abstract: The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: July 21, 2017
    Publication date: November 9, 2017
    Inventors: David S. Goldstein, Courtney Holmes, Rudolf-Giesbert Alken, Frank Schneider, Chengzhi Zhang
  • Patent number: 9763904
    Abstract: Herein described are deuterated catecholamine derivatives of the general Formula I wherein, R1 is deuterium, R2, and R3 are independently selected from hydrogen and deuterium and wherein at least one of R2 and R3 has a deuterium enrichment in the range from 0.02 mol % to 100 mol % deuterium, and wherein the deuterium enrichment of R2 and R3 is different from each other and that the difference between the deuterium enrichment of R2 and R3 is at least 5 percentage points, R4 is hydrogen, deuterium, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or C5 to C6-cycloalkyl, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions, as well as their physiologically acceptable salts and their stereoisomers, enantiomers or diastereomers in optically pure form. The compounds can easily be prepared by mixing deuterated and non-deuterated compounds in a predefined ratio. The compounds show anti-Parkinson effect at lower doses and show lower side effects.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: September 19, 2017
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Rudolf-Giesbert Alken, Frank Schneider
  • Publication number: 20170182024
    Abstract: Disclosed is a pharmaceutical composition comprising i) a dopamine agonist and ii) a L-DOPA derivative in combination in form of a liquid preparation. The pharmaceutical composition is used for the treatment of Parkinson's disease, restless leg syndrome, dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormones, for the treatment of neurological symptoms of chronic manganese intoxication, oamyotrophic lateral sclerosis, and multiple system atrophy.
    Type: Application
    Filed: March 11, 2015
    Publication date: June 29, 2017
    Inventors: Rudolf-Giesbert ALKEN, Frank SCHNEIDER
  • Publication number: 20170119716
    Abstract: Herein described are deuterated catecholamine derivatives of the general Formula I wherein, R1 is deuterium, R2, and R3 are independently selected from hydrogen and deuterium and wherein at least one of R2 and R3 has a deuterium enrichment in the range from 0.02 mol % to 100 mol % deuterium, and wherein the deuterium enrichment of R2 and R3 is different from each other and that the difference between the deuterium enrichment of R2 and R3 is at least 5 percentage points, R4 is hydrogen, deuterium, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or C5 to C6-cycloalkyl, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions, as well as their physiologically acceptable salts and their stereoisomers, enantiomers or diastereomers in optically pure form. The compounds can easily be prepared by mixing deuterated and non-deuterated compounds in a predefined ratio. The compounds show anti-Parkinson effect at lower doses and show lower side effects.
    Type: Application
    Filed: January 10, 2017
    Publication date: May 4, 2017
    Inventors: Rudolf-Giesbert Alken, Frank Schneider
  • Patent number: 9567289
    Abstract: Herein described are deuterated catecholamine derivatives of the general Formula (I) wherein R1 is deuterium, R2, and R3 are independently selected from hydrogen and deuterium and wherein at least one of R2 and R3 has a deuterium enrichment in the range from 0.02 mol % to 100 mol % deuterium, and wherein the deuterium enrichment of R2 and R3 is different from each other and that the difference between the deuterium enrichment of R2 and R3 is at least 5 percentage points, R4 is hydrogen, deuterium, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or C5 to C6-cycloalkyl, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions, as well as their physiologically acceptable salts and their stereoisomers, enantiomeres or diastereomers in optically pure form. The compounds can easily be prepared by mixing deuterated and non-deuterated compounds in a predefined ratio. The compounds show anti-Parkinson effect at lower doses and show lower side effects.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: February 14, 2017
    Assignee: ratiopharm GmbH
    Inventors: Rudolf-Giesbert Alken, Frank Schneider
  • Publication number: 20150376117
    Abstract: Herein described are deuterated catecholamine derivatives of the general Formula (I) wherein R1 is deuterium, R2, and R3 are independently selected from hydrogen and deuterium and wherein at least one of R2 and R3 has a deuterium enrichment in the range from 0.02 mol % to 100 mol % deuterium, and wherein the deuterium enrichment of R2 and R3 is different from each other and that the difference between the deuterium enrichment of R2 and R3 is at least 5 percentage points, R4 is hydrogen, deuterium, C1 to C6-alkyl or C5 to C6-cycloalkyl, deuterated C1 to C6-alkyl or C5 to C6-cycloalkyl, or a group that is easily hydrolytically or enzymatically cleavable under physiological conditions, as well as their physiologically acceptable salts and their stereoisomers, enantiomeres or diastereomers in optically pure form. The compounds can easily be prepared by mixing deuterated and non-deuterated compounds in a predefined ratio. The compounds show anti-Parkinson effect at lower doses and show lower side effects.
    Type: Application
    Filed: February 5, 2014
    Publication date: December 31, 2015
    Inventors: Rudolf-Giesbert ALKEN, Frank SCHNEIDER
  • Patent number: 8247603
    Abstract: The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: August 21, 2012
    Assignee: Birds Pharma GmbH Berolina Innovative
    Inventors: Rudolf-Giesbert Alken, Frank Schneider
  • Patent number: 8168820
    Abstract: The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically compatible salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: May 1, 2012
    Assignee: BDD Berolina Drug Development GmbH
    Inventor: Rudolf-Giesbert Alken
  • Publication number: 20090298893
    Abstract: Addition salts of 2,4?-dimethyl-3-piperidinopropiophenone (tolperisone) are described, wherein the salt is formed with an acid R—COOH and wherein R is the organic group of a physiologically compatible organic acid. Described also are processes for the preparation of these addition salts, the use thereof for pharmaceutical preparations and pharmaceuticals containing these addition salts.
    Type: Application
    Filed: March 21, 2006
    Publication date: December 3, 2009
    Inventors: Rudolf-Giesbert Alken, Frank Schneider
  • Publication number: 20090018191
    Abstract: The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
    Type: Application
    Filed: February 16, 2007
    Publication date: January 15, 2009
    Inventors: Rudolf-Giesbert Alken, Frank Schneider
  • Patent number: 7317039
    Abstract: The invention concerns deuterated substituted dihydrofuranones and pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated substituted dihydrofuranones for the treatment of symptoms for the irritating states of degenerative joint disorders, of acute pain and primary dysmenorrhea. In addition, the invention discloses pharmaceutical compositions, which contain deuterated substituted dihydrofuranones as well as their physiologically compatible salts, in addition to pharmaceutically compatible adjuvants and/or additives, for the treatment of symptoms for the irritating states of degenerative joint disorders, of acute pain and primary dysmenorrhea.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: January 8, 2008
    Assignee: BDD Berolina Drug Development GmbH
    Inventor: Rudolf-Giesbert Alken
  • Publication number: 20070082953
    Abstract: The present invention concerns the use of L-dopa, its derivatives or physiologically compatible salts thereof for the prophylaxis of psychotic disorders and for the treatment of diseases which are caused by disrupted tyrosine transport or disrupted tyrosine decarboxylase. In addition, the invention concerns pharmaceutical compositions which contain L-dopa, its derivatives or physiologically compatible salts thereof for the prophylaxis of psychotic disorders, in addition to pharmaceutically compatible adjuvants and additives.
    Type: Application
    Filed: December 18, 2003
    Publication date: April 12, 2007
    Inventor: Rudolf-Giesbert Alken
  • Publication number: 20060135615
    Abstract: The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically compatible salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
    Type: Application
    Filed: December 18, 2003
    Publication date: June 22, 2006
    Inventor: Rudolf-Giesbert Alken
  • Publication number: 20050222238
    Abstract: The invention concerns deuterated substituted pyrazolyl benzylsulfonamides as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated substituted pyrazolyl benzylsulfonamides for the treatment of symptoms of osteoarthritis and rheumatoid arthritis as well as for the prevention and treatment of neoplasia, in particular adenomatous colorectal polyps in familial adenomatous polyposis, for the treatment of pain, in particular acute pain and dysmenorrhea, in particular primary dysmenorrhea.
    Type: Application
    Filed: December 11, 2002
    Publication date: October 6, 2005
    Inventor: Rudolf-Giesbert Alken
  • Publication number: 20050176814
    Abstract: The invention concerns deuterated substituted dihydrofuranones and pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated substituted dihydrofuranones for the treatment of symptoms for the irritating states of degenerative joint disorders, of acute pain and primary dysmenorrhea. In addition, the invention discloses pharmaceutical compositions, which contain deuterated substituted dihydrofuranones as well as their physiologically compatible salts, in addition to pharmaceutically compatible adjuvants and/or additives, for the treatment of symptoms for the irritating states of degenerative joint disorders, of acute pain and primary dysmenorrhea.
    Type: Application
    Filed: December 11, 2002
    Publication date: August 11, 2005
    Inventor: Rudolf-Giesbert Alken
  • Patent number: RE46555
    Abstract: The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: September 19, 2017
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Rudolf-Giesbert Alken, Frank Schneider
  • Patent number: RE46629
    Abstract: The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically compatible salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: December 12, 2017
    Assignee: Teva Pharmaceuticals International GmbH
    Inventor: Rudolf-Giesbert Alken